The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAmid intensifying regulatory scrutiny over large-scale mergers, law firm Kahn Swick & Foti has launched legal investigations into the adequacy of proposed acquisition prices for several prominent US firms. The probes include the $31.50 per share offer for Catalyst Pharmaceuticals, the sale of Organon & Co. to Sun Pharmaceutical for $14.00 per share, and AbbVie’s acquisition of Apogee Therapeutics for $135.11 per share in cash. Additionally, the merger of Chicago Atlantic Real Estate Finance with Chicago Atlantic BDC is being scrutinized to determine if boards fulfilled their fiduciary duties to shareholders.
These investigations arrive during a period of robust M&A activity in the healthcare sector as giants like AbbVie move to bolster their drug pipelines. Per market data, OGN shares are currently trading at $13.43 (close June 18, 2026), slightly below the $14.00 offer price, reflecting investor caution regarding the closing timeline. While such legal challenges are a common fixture of Wall Street deal-making, they can occasionally force companies to provide additional disclosures or, in rarer cases, lead to improved offer terms for minority shareholders.
Traders should monitor price action for ABBV, which stood at $216.63 (close June 18, 2026), and OGN at $13.43 for any volatility linked to legal developments. Looking at the economic calendar, upcoming US Initial Jobless Claims and the Philadelphia Fed Manufacturing Index on June 18, 2026, may influence broader market sentiment toward growth and healthcare stocks. The outcome of these fairness opinions will be a key catalyst for the finalization of these multi-billion dollar transactions.